Immuno-oncology

T-Curx gains trial clearance for Siglec-6-targeted TCX-001

Thu, 11 Jun 2026 09:00:00 -0400

T-Curx GmbH has obtained clinical trial approval from the Swiss agency Swissmedic for the company’s nonviral lead CAR T program, TCX-001. The first-in-human phase I study will open in Switzerland, and a submission to the EMA will seek to expand the trial to sites in Germany. The study will enroll adults with relapsed or refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including patients not eligible for stem cell transplantation.

Antengene’s ATG-201 gains IND clearance in China

Wed, 10 Jun 2026 09:00:00 -0400

Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases.

Pheon Therapeutics discovers new CDCP1-targeting ADCs

Tue, 09 Jun 2026 09:00:00 -0400

Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.

Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome

Tue, 09 Jun 2026 09:00:00 -0400

The University of Oxford and Moderna Inc. have announced authorization by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of mRNA-4194, Moderna’s investigational mRNA-based cancer vaccine for Lynch syndrome.

AxS007 penetrates BBB for breast cancer brain metastases

Fri, 05 Jun 2026 09:00:00 -0400

About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure.

Sotio Biotech’s SOT-106 designated orphan drug for osteosarcoma

Thu, 04 Jun 2026 09:00:00 -0400

Sotio Biotech AS’s SOT-106 has been granted orphan drug designation by the FDA for the treatment of osteosarcoma. SOT-106 is a next-generation antibody-drug conjugate targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumor-associated stroma.

IMU’s $53M series A to advance high-definition immune profiling tech

Wed, 03 Jun 2026 09:00:00 -0400

IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.

CSPC’s SYS-6063 gains Chinese trial clearance for SLE

Wed, 03 Jun 2026 09:00:00 -0400

CSPC Pharmaceutical Group Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration (NMPA) for SYS-6063, an mRNA-LNP-based dual-target CAR T-cell injection for the treatment of relapsed or refractory systemic lupus erythematosus (SLE).

IMU’s $53M series A to advance high-definition immune profiling tech

Tue, 02 Jun 2026 12:00:00 -0400

FDA approves IND for Iovance’s TIL therapy IOV-5001

Tue, 02 Jun 2026 09:00:00 -0400

Iovance Biotherapeutics Inc. has received IND clearance from the FDA for IOV-5001, a next-generation interleukin-12 (IL-12)-tethered tumor-infiltrating lymphocyte (TIL) therapy.

Series A financing at Waypoint Bio supports CAR T programs

Tue, 02 Jun 2026 09:00:00 -0400

Waypoint Bio has closed a $20 million series A financing round to support its work developing next-generation in vivo CAR T therapeutics for solid tumors using a platform that integrates AI, computer vision and spatial pooled screening.

Replimune tries again with melanoma drug post FDA shakeup

Fri, 29 May 2026 12:00:00 -0400

Industry watchers will be tracking closely Replimune Group Inc.’s latest attempt to secure U.S. FDA approval of its advanced melanoma candidate, RP-1 (vusolimogene oderparepvec). The company announced Friday it had reached alignment for resubmitting the twice-rejected BLA with the agency, which it said has pledged to prioritize the review.

Zhize Tongkang (Guangzhou) Biotechnology prepares new anti-CLDN6 ADCs

Fri, 29 May 2026 09:00:00 -0400

Zhize Tongkang (Guangzhou) Biotechnology Co. Ltd. has divulged new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting claudin 6 (CLDN6) linked to a camptothecin derivative potentially useful for the treatment of cancer and fibrosis.

ALG-093940 shows promise for liver cancer and hepatitis B

Fri, 29 May 2026 09:00:00 -0400

Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the characterization of ALG-093940, a small molecule PD-1/PD-L1 inhibitor that induces PD-L1 dimerization and degradation.

Anti-EGFR antibody-drug conjugates reported in Hutchmed patent

Thu, 28 May 2026 09:00:00 -0400

Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases.

Reprogram Biosciences secures financing for solid tumor mRNA work

Thu, 28 May 2026 09:00:00 -0400

Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025.

Oricell’s OriC-902 shows robust results in HCC

Thu, 28 May 2026 09:00:00 -0400

At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC).

KLS-3021 suppresses tumors and induces immune memory in TNBC

Wed, 27 May 2026 09:00:00 -0400

Kolon Life Science Inc. is developing KLS-3021, a next-generation oncolytic vaccinia virus designed to express the PH20, IL-12 and PD-1-Fc transgenes to mediate receptor-independent tumor cell killing and enhance antitumor immune responses.

Biomunex enters AI partnerships to advance cancer immunotherapies

Wed, 27 May 2026 09:00:00 -0400

Biomunex Pharmaceuticals SAS has entered into strategic collaborations with two AI-specialized companies – Gordion Bioscience Inc. and Tangramed Biotech SAS – as part of its strategy to integrate AI into its R&D activities and support the development of next-generation immunotherapies in oncology.

Kunshan Xinyunda Biotechnology synthesizes new ADAM9-targeting ADCs

Tue, 26 May 2026 09:00:00 -0400

Kunshan Xinyunda Biotechnology Co. Ltd. has patented new antibody-drug conjugates (ADCs) consisting of humanized antibodies targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) covalently linked to a payload and potentially useful for the treatment of cancer and inflammatory disorders.

Researchers identify innate immune barrier against melanoma

Tue, 26 May 2026 09:00:00 -0400

Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live melanoma cells, and the discovery could reshape thinking around macrophage-targeted cancer therapies and innate immunity in oncology.

Asgard’s AT-108 shows promise as immunotherapeutic

Fri, 22 May 2026 09:00:00 -0400

Defects in antigen presentation lead to resistance to cancer immunotherapy, where type I conventional dendritic cells (cDC1s) are crucial drivers of antitumor immunity and their presence is tied to favorable responses and better outcomes. Intratumoral delivery of adenoviral vector, Ad5-PIB, encoding PU.1, IRF8 and BATF3 reprograms tumor cells into cDC1-like antigen-presenting cells and has shown synergy with immune checkpoint blockade (ICB) therapy at exerting antitumor immunity. Asgard Therapeutics AB has developed AT-108, a lead candidate developed for durable efficacy.

Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma

Fri, 22 May 2026 09:00:00 -0400

Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is based on its Vivovec technology and designed to engineer fully human anti-B-cell maturation antigen (BCMA)/G protein-coupled receptor class C group 5 member D (GPRC5D) dual-targeting chimeric antigen receptor (CAR) T cells, for the potential treatment of multiple myeloma (MM).

Henlius gains Australian trial clearance for HLX-3902

Fri, 22 May 2026 09:00:00 -0400

Shanghai Henlius Biotech Inc.’s HLX-3902, a trispecific antibody targeting STEAP1xCD3xCD28, has received approval from the Human Research Ethics Committee (HREC) in Australia and has been filed with the Therapeutic Goods Administration (TGA). The T-cell engager is intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors.

Ichnos Glenmark Innovation unveils ISB-2301 for solid tumors

Thu, 21 May 2026 09:00:00 -0400

Ichnos Glenmark Innovation Inc. has announced a new development candidate, ISB-2301, a potentially first-in-class, multispecific immune cell activator for the potential treatment of multiple solid tumor indications. ISB-2301 is a multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death and engages both T and NK cells to activate the immune system. Leveraging the company’s BEAT technology, ISB-2301 is designed to induce potent antibody-dependent cellular cytotoxicity, checkpoint inhibition and a sustained type 1 immune response.

Matter Bio files IND for Lm-LLO-TT for PDAC

Wed, 20 May 2026 09:00:00 -0400

Matter Bio has submitted its first IND application to the FDA for Lm-LLO-TT, the company’s lead therapeutic candidate, seeking to initiate a first-in-human phase I/IIa trial in patients with pancreatic ductal adenocarcinoma (PDAC).

Iksuda and UCL report new B7-H3-targeting ADCs

Tue, 19 May 2026 09:00:00 -0400

Iksuda Therapeutics Ltd. and UCL Business Ltd. have prepared new antibody-drug conjugates comprising antibodies targeting B7 homolog 3 (B7-H3, CD276) covalently linked to cytotoxic drug, designed for potential use in the treatment of cancer.

Dual-payload ADC holds promise for treating HER2+ tumors

Tue, 19 May 2026 09:00:00 -0400

Antibody-drug conjugates (ADCs) with a dual payload, which deliver two distinct cytotoxic agents via a single antibody, are emerging therapeutics developed to address the limitations of classic ADCs. Primelink Biotherapeutics (Shenzhen) Co. Ltd. recently presented data for their dual-payload ADCs, highlighting PLB-015, which carries a TOP1 inhibitor and an ATR inhibitor with an anti-HER2 antibody and is designed to inhibit the DNA damage response activated by cancer cells when harmed.

MD Anderson gains IND nod for CD94-targeted CAR T therapy

Mon, 18 May 2026 09:00:00 -0400

The University of Texas MD Anderson Cancer Center has received IND clearance from the FDA to initiate a phase I trial of a novel CAR T-cell therapy, JV-394, for patients with relapsed or refractory CD94-positive T/natural killer (NK) cell lymphomas.

Antelope Therapeutics patents new antibody-drug conjugates for cancer

Fri, 15 May 2026 09:00:00 -0400

A recent Antelope Therapeutics SAS patent describes new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting canAg (CA242) mucin glycoepitope covalently linked to exatecan designed for use in the treatment of cancer.